{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:49:54Z","timestamp":1787788194621,"version":"build-2784847793"},"reference-count":131,"publisher":"PAGEPress Publications","issue":"4","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatismo"],"abstract":"<jats:p>Objective. Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that typically requires management with immunosuppressive and anti-inflammatory treatments. The 2023 guidelines of the European Alliance of Associations for Rheumatology now recommend lowering maintenance glucocorticoid doses to \u22645 mg\/day to reduce long-term health risks, a decrease from the previous 7.5 mg\/day threshold set in 2019. To help achieve these reduced doses, early initiation of biologic therapies is suggested, even before conventional immunosuppressants. Belimumab and anifrolumab, the biologics currently approved for SLE treatment, have shown greater efficacy than placebo in clinical trials and similar safety profiles, supporting their use in achieving remission and enabling glucocorticoid tapering or discontinuation. This review evaluates the role of biologics, especially anifrolumab, in treating extra-renal SLE in Italy, using clinical scenarios to illustrate situations where early anifrolumab therapy could be beneficial.\nMethods. Hypothetical scenarios derived from clinical practice were examined to identify real-life contexts suitable for the early initiation of anifrolumab treatment.\nResults. Anifrolumab represents an effective therapeutic option for various extra-renal SLE patients. These include those who have failed to achieve or maintain remission with standard care, have contraindications to conventional immunosuppressants, are glucocorticoid-dependent, or experience mucocutaneous and musculoskeletal manifestations. Anifrolumab also offers potential benefits for patients planning pregnancy by promoting remission or low disease activity.\nConclusions. Despite its recent approval and limited real-world evidence, anifrolumab has emerged as a promising therapeutic option for non-renal lupus. We hope this review will encourage further studies on the efficacy and safety of anifrolumab in real-life SLE patient cohorts.<\/jats:p>","DOI":"10.4081\/reumatismo.2025.1830","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T09:19:22Z","timestamp":1753262362000},"source":"Crossref","is-referenced-by-count":2,"title":["The role of anifrolumab in reshaping the treatment landscape of extra-renal systemic lupus erythematosus"],"prefix":"10.4081","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5026-8783","authenticated-orcid":false,"given":"Fulvia","family":"Ceccarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1126-8315","authenticated-orcid":false,"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-8134","authenticated-orcid":false,"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7289","authenticated-orcid":false,"given":"Laura","family":"Coladonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Fredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"13723","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272"},{"key":"13724","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223741"},{"key":"13725","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0133-2"},{"key":"13726","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05306-5"},{"key":"13727","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225617"},{"key":"13728","doi-asserted-by":"publisher","DOI":"10.1002\/art.40571"},{"key":"13729","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538corr1"},{"key":"13730","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew377"},{"key":"13731","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222487"},{"key":"13732","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac185"},{"key":"13733","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-023-00358-3"},{"key":"13734","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew406"},{"key":"13735","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00948-y"},{"key":"13736","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"13737","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105523"},{"key":"13738","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"13739","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"13740","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"13741","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962"},{"key":"13742","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"13743","doi-asserted-by":"publisher","DOI":"10.1002\/art.42392"},{"key":"13744","unstructured":"Hitt E. Belimumab earns FDA approval for lupus. Available from: https:\/\/www.medscape.com\/viewarticle\/738729."},{"key":"13745","doi-asserted-by":"publisher","DOI":"10.1002\/art.41253"},{"key":"13746","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040691"},{"key":"13747","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11482"},{"key":"13748","unstructured":"Costenbader K, Abe Y, Anaud L, Bertsias G, Fox NL, Gibb M, et al. Reduction in glucocorticoid use in patients with systemic lupus erythematosus treated with belimumab: a large pooled analysis of 5 placebo-controlled studies [abstract]. Arthritis Rheumatol 2021; 73."},{"key":"13749","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000118"},{"key":"13750","doi-asserted-by":"publisher","DOI":"10.1002\/art.39682"},{"key":"13751","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2022.08.001"},{"key":"13752","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3682-9"},{"key":"13753","unstructured":"AIFA. Determina 20 marzo 2023. Avaialble from: https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina_221-2023_Saphnelo.pdf. [Material in Italian]."},{"key":"13754","unstructured":"AIFA. Determina 7 ottobre 2021. Available from: https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina_1213-2021_Benlysta.pdf. [Material in Italian]."},{"key":"13755","unstructured":"EMA. Annex I. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/saphnelo-epar-product-information_en.pdf."},{"key":"13756","unstructured":"EMA. Annex I. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf%20Last%20access%20March%206."},{"key":"13757","unstructured":"FDA. Benlysta. Highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761043s021lbl.pdf."},{"key":"13758","unstructured":"FDA. Saphnelo. Highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761123s000lbl.pdf."},{"key":"13759","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-024-01092-2"},{"key":"13760","unstructured":"Gross A. China market access for drugs is tougher, but some daylight too. Available from: https:\/\/www.pacificbridgemedical.com\/uncategorized\/china-market-access-for-drugs-is-tougher-but-some-daylight-too\/."},{"key":"13761","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045934"},{"key":"13762","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket322"},{"key":"13763","doi-asserted-by":"publisher","DOI":"10.1002\/art.24741"},{"key":"13764","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.1568"},{"key":"13765","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121368"},{"key":"13766","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000761"},{"key":"13767","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215732"},{"key":"13768","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead696"},{"key":"13769","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222748"},{"key":"13770","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24086"},{"key":"13771","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.2918"},{"key":"13772","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead568"},{"key":"13773","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318817132"},{"key":"13774","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30546-X"},{"key":"13775","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.45132"},{"key":"13776","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003588"},{"key":"13777","doi-asserted-by":"publisher","DOI":"10.1002\/art.40861"},{"key":"13778","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22938"},{"key":"13779","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000078"},{"key":"13780","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819"},{"key":"13781","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200831"},{"key":"13782","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000286"},{"key":"13783","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2023.2247881"},{"key":"13784","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxad055"},{"key":"13785","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(02)00016-5"},{"key":"13786","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.01.003"},{"key":"13787","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.008"},{"key":"13788","unstructured":"Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol 1994; 21: 1665-9."},{"key":"13789","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213197"},{"key":"13790","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.008"},{"key":"13791","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19918-z"},{"key":"13792","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00774-8"},{"key":"13793","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01604-z"},{"key":"13794","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00317-9"},{"key":"13795","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221425"},{"key":"13796","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15335"},{"key":"13797","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0175"},{"key":"13798","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad089"},{"key":"13799","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001007"},{"key":"13800","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39553"},{"key":"13801","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123449"},{"key":"13802","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11206016"},{"key":"13803","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101859"},{"key":"13804","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317716319"},{"key":"13805","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.04.005"},{"key":"13806","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.007"},{"key":"13807","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes226"},{"key":"13808","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead241"},{"key":"13809","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00398-2"},{"key":"13810","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0120"},{"key":"13811","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209770"},{"key":"13812","unstructured":"ISS. La salute riproduttiva nei pazienti con malattie reumatologiche. Available from: https:\/\/www.iss.it\/it\/web\/guest\/-\/salute-riproduttiva-in-pazienti-con-malattie-reumatologiche."},{"key":"13813","doi-asserted-by":"publisher","DOI":"10.1002\/art.41191"},{"key":"13814","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac686"},{"key":"13815","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03298-6"},{"key":"13816","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1033404"},{"key":"13817","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X19847832"},{"key":"13818","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02699-1"},{"key":"13819","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001036"},{"key":"13820","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2023.12.039"},{"key":"13821","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03256-8"},{"key":"13822","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.005"},{"key":"13823","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez422"},{"key":"13824","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0621-3"},{"key":"13825","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep062"},{"key":"13826","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab155"},{"key":"13827","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217070"},{"key":"13828","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211613"},{"key":"13829","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01824-x"},{"key":"13830","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.651249"},{"key":"13831","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315627202"},{"key":"13832","unstructured":"EMA. Saphnelo. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/saphnelo."},{"key":"13833","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212504"},{"key":"13834","unstructured":"Kalunian K, Dall\u2019Era M, Furie R, Psachoulia K, Maho E, Lindholm C, et al. Anifrolumab results in favorable responses regardless of SLE disease duration: post hoc analysis of data from 2 Phase 3 trials [abstract]. 2021; 73 (suppl 9). Accessed March 26, 2024. Arthritis Rheumatol 2021; 73: 1741."},{"key":"13835","unstructured":"113. Manzi S, Furie R, Morand E, Abreu G, Lindholm C, Raj Tummala R. SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials. Arthritis Rheumatol 2021; 73: 1739."},{"key":"13836","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead166"},{"key":"13837","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224919"},{"key":"13838","doi-asserted-by":"publisher","DOI":"10.1002\/art.21658"},{"key":"13839","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.03.018"},{"key":"13840","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2263"},{"key":"13841","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03297.x"},{"key":"13842","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06784.x"},{"key":"13843","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2012.10"},{"key":"13844","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34175"},{"key":"13845","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/g4rby6"},{"key":"13846","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00304-6"},{"key":"13847","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead348"},{"key":"13848","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210154"},{"key":"13849","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002701"},{"key":"13850","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207347"},{"key":"13851","unstructured":"Urowitz MB, Feletar M, Bruce IN, Iba\u00f1ez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32: 1467-72."},{"key":"13852","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478"},{"key":"13853","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211014267"}],"container-title":["Reumatismo"],"original-title":[],"link":[{"URL":"https:\/\/www.reumatismo.org\/reuma\/article\/download\/1830\/1090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.reumatismo.org\/reuma\/article\/download\/1830\/1090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:02:21Z","timestamp":1764086541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.reumatismo.org\/reuma\/article\/view\/1830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":131,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,24]]}},"URL":"https:\/\/doi.org\/10.4081\/reumatismo.2025.1830","relation":{},"ISSN":["2240-2683","0048-7449"],"issn-type":[{"value":"2240-2683","type":"electronic"},{"value":"0048-7449","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}